Premature delivery and PI-based ARVs
Researchers from the French Perinatal Cohort study found that women who began ritonavir-boosted protease inhibitor threapy to treat HIV during pregnancy were more likely to have a premature delivery than those on other combination therapies and twice as likely to have a premature delivery than the general French population. As the use of ritonavir-boosted therapy becomes standard of care, further research is warranted.
Citation:
Sibiude J, Warszawski J, Tubiana R, Dollfus C, Faye A, Rouzioux C, Teglas JP, Ekoukou D, Blanche S, Mandelbrot L. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: Role of the ritonavir boost? Clin Infect Dis. 2012 Mar 28. [Epub ahead of print].
Original Article (subscription may be required)
Abstract
Citation:
Sibiude J, Warszawski J, Tubiana R, Dollfus C, Faye A, Rouzioux C, Teglas JP, Ekoukou D, Blanche S, Mandelbrot L. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: Role of the ritonavir boost? Clin Infect Dis. 2012 Mar 28. [Epub ahead of print].
Original Article (subscription may be required)
Abstract
